Evaluation of the Efficacy and Safety of Telitacicept combined with MMF or Low-dose Hormones in Patients with IgAN with Low Proteinuria (0.5-1g/d)

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 3692ec3a150d65958c76774c3b3a44448624aa77
First added on: Oct 10, 2026